Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe

被引：12

作者：

Akhmetov, Ildar ^{[1
]}

Ramaswamy, Rakshambikai ^{[1
]}

Akhmetov, Illias ^{[2
]}

Thimmaraju, Phani Kishore ^{[1
]}

机构：

[1] Phamax Analyt Resources Pvt Ltd, 19,KMJ Ascend 1st Cross,17th C Main 5th Block, Koramangala Bangalore 560095, India

[2] Unicorn, UA-10020 Zhytomyr, Ukraine

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2015年 / 5卷 / 02期

关键词：

Stratified medicine; companion diagnostics; market access; cost-effectiveness; value addition;

D O I：

10.3390/jpm5020213

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

引用

页码：213 / 228

页数：16

共 30 条

[11] Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non-Small-Cell Lung Cancer
Falconi, Adam
Lopes, Gilberto
Parker, Jayson L.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) : 163 - 169
[12] Challenges in the Development and Reimbursement of Personalized Medicine-Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
Faulkner, Eric
Annemans, Leven
Garrison, Lou
Helfand, Mark
Holtorf, Anke-Peggy
Hornberger, John
Hughes, Dyfrig
Li, Tracy
Malone, Daniel
Payne, Katherine
Siebert, Uwe
Towse, Adrian
Veenstra, David
Watkins, John
[J]. VALUE IN HEALTH, 2012, 15 (08) : 1162 - 1171
[13] FDA, LIST CLEAR APPR COMP
[14] Garfield S., ADV ACCESS PERSONALI
[15] Groves E., BIOMARKERS DIAGNOSTI
[16] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
Higashi, MK
Veenstra, DL
Kondo, LML
Wittkowsky, AK
Srinouanprachanh, SL
Farin, FM
Rettie, AE
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1690 - 1698
[17] Kanavos P, MANAGED ENTRY AGREEM
[18] Kievits T., PERSONALISED MED CLI
[19] Markus B., PERSONALISED MED EUR
[20] Market access challenges in the EU for high medical value diagnostic tests
Miller, Iain
Ashton-Chess, Joanna
Spolders, Herman
Fert, Vincent
Ferrara, Joseph
Kroll, Werner
Askaa, Jon
Larcier, Patrick
Terry, Patrick F.
Bruinvels, Anne
Huriez, Alain
[J]. PERSONALIZED MEDICINE, 2011, 8 (02) : 137 - 148

← 1 2 3 →